Methodological Considerations for Studies in Sport and Exercise Science with Women as Participants: A Working Guide for Standards of Practice for Research on Women

Kirsty J. Elliott-Sale1 · Clare L. Minahan2 · Xanne A. K. Janse de Jonge3 · Kathryn E. Ackerman4 · Sarianna Sipilä5 · Naama W. Constantini6 · Constance M. Lebrun7 · Anthony C. Hackney8

Accepted: 6 February 2021 / Published online: 16 March 2021 © The Author(s) 2021

Abstract

Until recently, there has been less demand for and interest in female-specific sport and exercise science data. As a result, the vast majority of high-quality sport and exercise science data have been derived from studies with men as participants, which reduces the application of these data due to the known physiological differences between the sexes, specifically with regard to reproductive endocrinology. Furthermore, a shortage of specialist knowledge on female physiology in the sport science community, coupled with a reluctance to effectively adapt experimental designs to incorporate female-specific considerations, such as the menstrual cycle, hormonal contraceptive use, pregnancy and the menopause, has slowed the pursuit of knowledge in this field of research. In addition, a lack of agreement on the terminology and methodological approaches (i.e., gold-standard techniques) used within this research area has further hindered the ability of researchers to adequately develop evidenced-based guidelines for female exercisers. The purpose of this paper was to highlight the specific considerations needed when employing women (i.e., from athletes to non-athletes) as participants in sport and exercise science-based research. These considerations relate to participant selection criteria and adaptations for experimental design and address the diversity and complexities associated with female reproductive endocrinology across the lifespan. This statement intends to promote an increase in the inclusion of women as participants in studies related to sport and exercise science and an enhanced execution of these studies resulting in more high-quality female-specific data.

1 Introduction

1.1 Statement of the Problem

Across the lifespan, circulating concentrations of oestrogen and progesterone change from puberty, through adulthood, until menopause, when a dramatic decline in the secretion of ovarian steroids occurs and cyclic oestrogen production is replaced by a low constant production by the ovaries. Furthermore, between puberty and menopause, circulating concentrations of oestrogen fluctuate fivefold and progesterone greater than 50-fold over a 21- to 35-day cycle (i.e., menstrual cycle). Indeed, these cyclical acute fluctuations in ovarian hormones across the menstrual cycle may be altered by external factors (e.g., hormonal contraceptives [HC], circadian variation, diet, exercise), clinical conditions

Key Points

Not all ‘women’ are the same. Women have a variety of reproductive hormonal profiles that change across the lifespan from puberty to the menopause.

The endogenous hormonal profile of women is frequently influenced by exogenous sources, such as hormonal contraceptives (HC) and hormone replacement therapy (HRT).

Depending on the research question, women should be recruited on pre-defined, standardised criteria, which, in most cases, should be retrospectively confirmed (i.e., homogenous a priori inclusion and a posteriori exclusion criteria).

Depending on the research question, the experimental design needs to be adapted in line with the hormonal milieu (e.g., consideration of menstrual cycle phase, type of HC used, stage of menopause).
(e.g., functional hypothalamic amenorrhea, polycystic ovary syndrome) and pregnancy (Fig. 1; [1]).

In addition to reproductive function, ovarian steroids have been shown to target a number of tissues (e.g., epithelial, connective, muscle and nervous; [2–4]) and influence an array of biological processes (e.g., metabolism, ventilation, immunity, cognition, gastrointestinal, cardiovascular, autonomic regulation, and genitourinary function; [5–13]). As such, different concentrations of circulating ovarian steroids throughout the lifespan and across the menstrual cycle (with and without dysfunction and/or manipulation) might significantly influence the mechanisms that control and regulate cell function and integrated physiologic adaptation in women.

Given the potential influence of ovarian hormones on multiple biological systems, it is reasonable to assume that the heterogeneous findings observed among studies conducted with women as participants, particularly those examining physiological responses to exercise and adaptations to training, may be attributable to the numerous hormonal profiles a woman may experience during her lifetime. As such, it is important that scientists consider the potential effects of ovarian hormones throughout the lifespan on exercise responses and sports performance and apply suitable methodology to their studies in order to control these effects and reduce the heterogeneous results. Nonetheless, for decades scientists have avoided conducting sport and exercise research with women as participants due, in part, to the complex methodological considerations required and/or the difficulty in interpreting the heterogeneous results often observed within and among studies. Consequently, research findings from sport and exercise performance and training studies with men only as participants are applied to women, which can result in a missed opportunity for women to reach their athletic and performance potential.

1.2 Current State of the Art

Research into the effects of the menstrual cycle on the exercise response has been ongoing since at least 1876, when Professor Mary Jacobi won the Harvard University Boylston Prize Essay for her observations on menstruation and physical work and rest [14]. Despite a recent growing interest in research in sport and exercise science with women as participants, the overall research quantity in this area is still very small compared to research with men as participants [15]. Therefore, the effects of oestrogen and progesterone on women’s responses to exercise and adaptations to training are still not fully understood. As a result, there are no sport and exercise-related guidelines for training and nutrition which are customised for sportswomen (i.e., athletes and exercisers) and underpinned by sufficient, high-quality scientific evidence. Numerous reviews [e.g., 16–20], books

![Fig. 1 Indicative oestrogen and progesterone profiles across the lifespan from childhood to senescence: a оestrogen (pmol·L⁻¹). With regards to oestrogen, the menstrual cycle has 20 times more oestrogen than pre-puberty and pregnancy 35 times more oestrogen than the menstrual cycle; b progesterone (nmol·L⁻¹). The menstrual cycle has 35 times more progesterone than pre-puberty and pregnancy almost 7 times more progesterone than during the menstrual cycle. Oral contraceptives users and post-menopausal women have similar levels of endogenous oestrogen and progesterone. Hypothalamic-pituitary forms of amenorrhea (not depicted here) do not show any evidence of oestrogen production based on urinary measurements [1]. In women, “oestrogen” includes the oestrone, oestradiol, oestriol hormones](image-url)
[e.g., 21–23] and meta-analyses [e.g., 24, 25] have summarised and examined data from this field spanning almost 50 years, but all have concluded that more, better quality studies are needed before a consensus on the effects of ovarian steroids on training and performance can be reached.

It is clear that more research focusing on areas unique to female physiology is required to inform best practice guidelines for training and nutrition. [24, 25]. There are some studies, however, that have demonstrated clear and recurring findings of ovarian-steroid interference with biological processes that may affect athletic performance (i.e., responses to exercise and adaptation to, and recovery from, training), which highlight the importance of considering ovarian steroid profiles in sport and exercise science research. In particular, the manipulation of endogenous ovarian steroid levels with synthetic hormones (i.e., HC) has been repeatedly associated with increased markers of muscle damage in women after unaccustomed eccentric exercise [8, 26–30]. Therefore, knowledge of the use of HC by athletes or research participants is imperative in understanding the recovery process after an acute bout of exercise or adaptation to training. There is a strong body of evidence indicating altered thermoregulation in women taking HC during exercise including altered skin blood flow and cutaneous vasodilation, as well as a delayed onset of sweating and a higher internal temperature threshold [31–35]. As such, ovarian hormone interference via the administration of HC may have implications for exercise in the heat. Oestrogen is often associated with substrate oxidation and utilisation during prolonged exercise. The notion that elevated plasma oestrogen concentrations increase the reliance on fat as an energy source during endurance exercise is a consistent observation [6, 36–38]. Despite these few convincing findings, whether disturbances to these physiological mechanisms result in a decrement to performance in strength, speed, and/or endurance events remains to be elucidated. It should be also noted that there is always at least one study that opposes the findings of the majority and as newer formulations of synthetic hormones are developed, there will be further ambiguity in the findings. Therefore, the importance of considering a woman’s current ovarian hormonal profile in sport and exercise science research is paramount.

### 1.3 The Gap in the Field

Rather than viewing the dynamic profiles of ovarian steroids in women as a reason to exclude them from sport and exercise science research, future studies need to explore the specific effects of oestrogen and progesterone and related hormonal ageing on physiological function and ergo athletic performance across the lifespan in women. Female-specific research is needed as the number of women participating in sport and exercise is increasing in many countries, and parity in the Olympics and Paralympics is approaching (i.e., equal number of male and female competitors and medals). For example, in 1900 only 2.2% of the competitors in the Olympics were female; in 1952 the proportion was 10.5%, in 2000 it was 38.2% and in 2021 it is predicted to be 48.8%. If male-based research continues to be applied to females, there is a risk that the true potential of women will not be achieved as the potential influence of ovarian hormones remains unclear; herein exist the gap in the field and the fundamental statement of the problem within contemporary sport and exercise science. At the elite level, understanding the effects of oestrogen and progesterone on body systems and performance may produce the marginal gain needed for success. In addition, there is a need to understand the effects of training on hypothalamic, pituitary and ovarian hormones and related outcomes, such as body composition and bone [39]. At the recreational level, understanding the impact of changes in ovarian hormone concentration, experienced during the menstrual cycle or as a result of menstrual irregularities, hormonal contraceptive use, pregnancy or the menopause, on the ability and willingness to undertake exercise and physical activity may help reduce the disproportionate decline in sports participation seen at puberty in girls [40, 41]. This decrease in physical activity often extends into adulthood, and is compounded during pregnancy and the postpartum period [22], and as such has implications for health and well-being [42] for women of all ages. Among middle-aged women, menopausal hormonal changes are associated with deterioration of the body systems [43], performance and functioning [44], but further understanding is needed of the magnitude and timing of these changes as well as the role of physical activity and exercise to overcome or attenuate these changes.

In order to facilitate a new generation of quality research in sport and exercise science with women as participants that addresses the current gap in the field, direction is needed on the best and most accurate types of research design to employ in this field. In addition, guidance on the definition(s) of sampled populations is required in order to improve the uniformity of studies involving women. As such, this article is intended to serve as a working guide for standards of practice for research on women.

Synchronous with changes in performance, ovarian steroids exert many clinical effects, which have also received less attention in sport and exercise medicine-based research. Examples include hyponatremia, which is more prevalent in females than males [45] and heat stroke, which is influenced by ovarian hormonal concentrations [46]. Although this paper is focused on studies related to sport and exercise science, some of the approaches described herein may be also relevant for female-based sport and exercise medicine-based research.
1.4 Background to the Statement

In the early 2000s, articles started to provide critical commentary on the methodological approach used in studies investigating the effects of oestrogen and progesterone on different aspects of exercise performance [18, 47]. This began to raise an awareness of some of the technical flaws and issues within this field. Cable and Elliott [47] focused on the methodological approach used in studies investigating the effects of ovarian steroids on muscle strength in women. They identified inconsistencies in terminology and research design, namely differences in the definition of reproductive status (e.g., inconsistencies in menstrual cycle phase definition), often leading to the grouping of non-homogeneous participants; and quantification of reproductive status, by using inaccurate and subjective methods. In addition, they highlighted that consideration needed to be given to characteristics of the hormonal milieu; such as, if the changes in ovarian steroids were acute (e.g., menstrual cycle) or chronic (e.g., menopause); within normal (e.g., menstrual cycle) or supra-physiological (e.g., pregnancy) ranges; caused by endogenous fluctuations (e.g., menstrual cycle) or exogenous (e.g., HC or hormone replacement therapy [HRT]) supplementation. The review by Janse de Jonge [18] focussed on methodological considerations in menstrual cycle research, including the verification of menstrual cycle phase and the timing of testing throughout the cycle. More recently, Janse de Jonge et al. [48] consolidated the approaches and issues observed specifically in menstrual-cycle studies and proposed methodological guidelines for undertaking menstrual cycle-based research in sport and exercise science. Furthermore, broad methodological considerations for studies in exercise endocrinology have been provided lately [49], including the critical consideration of sex and the menstrual cycle. The current statement builds upon these reviews by providing guidance for studies including women from across the lifespan.

1.5 Approach to the Statement

The considerations outlined herein are based on previous research and expert opinion and are delivered alongside the rationale and pros and cons for each method. Where appropriate the primary source has been provided; however, some items have been specifically developed for this statement. For ease of reading we are using oestrogen throughout the paper, but recognise this encompasses oestradiol, oestrone and oestriol. For more detailed information on female endocrinology see Hackney [21].

1.6 Purpose of the Statement

The aim of this statement was to consolidate the opinions, lessons and evidence from experienced researchers in the area of women’s physiology, with a view to providing counsel for those beginning to pursue research in this very important area. Moreover, the considerations described herein are intended to help dispel the myths and poor practices commonly associated with this subject area, thus improving the quality of future research and allowing more meaningful comparisons to be made between studies that have employed consistent terminology and research designs. Overall, this statement aims to contribute to advancing the scientific community’s knowledge and understanding of women’s physiology in the context of sport and exercise science.

2 Considerations

2.1 Participants

Much of the heterogeneity in this area of research is derived from the lack of uniformity when describing the populations used in studies with women as participants. While chronological age is often controlled and reported, maturation status and menstrual-cycle status (i.e., length, irregularities/dysfunction, manipulation) are more often not. Moreover, if menstrual-cycle status is even considered by researchers, the hormonal profile of the participants is often implied rather than confirmed [25] which may exacerbate the variability between studies.

In order to overcome these issues, consistency is needed in the following: (i) the terminology used to describe participants; and (ii) the inclusion/exclusion criteria, specifically the hormonal parameters, used to define eligible participants. This uniformity will allow meaningful comparison within and among studies (i.e., comparing like with like). Table 1 proposes a framework of terms and conditions, based on previous research and our collective experience and expertise in the field that could help to ensure consistency in women’s sport and exercise-based studies. Across the lifespan, the ovarian steroids start changing at puberty. Therefore, the stage of puberty needs to be classified consistently in research with younger populations. During the reproductive years there are five main factors that will influence the fluctuations in oestrogen and progesterone: i) fluctuations across the eumenor-rheic menstrual cycle; ii) disruptions to the eumenorrheic menstrual cycle caused by illness or disease (e.g., polycystic ovary syndrome, endometriosis or other hypothalamic pituitary axis disruptions), low energy availability, the first two years after menses, and the time nearing menopause; iii) manipulation of the eumenorrheic menstrual cycle with exogenous hormones, both synthetic and natural (e.g., HC and HRT); iv) pregnancy (increasing ovarian steroids profile); and v) menopause (decreasing ovarian steroids
profile). Researchers should strive to adopt all recommendations that are appropriate, thus facilitating good practice in this area.

### 2.2 Experimental Design

The experimental design employed in studies with women as participants is often poorly considered, described, controlled and/or executed, which is mainly due to a lack of understanding of the hormonal changes experienced across the lifespan in women. In addition, studies involving women as participants usually require repeated measures due to the acute (e.g., ultradian, circadian and infradian rhythms) and chronic fluctuations (e.g., pregnancy, menopause, HC and HRT usage) in reproductive hormones over time, unlike in studies with men as participants who have relatively stable (i.e., outside of circadian variation) sex hormone profiles following puberty. Table 2 outlines some methodological approaches that could be employed at various stages of the life cycle (i.e., puberty, menstrual cycle and irregularities, hormonal contraception, pregnancy and menopause) in women.

One particular aspect of research design that has continued to cause debate amongst authors and disparity between studies is the nomenclature associated with the phases of the menstrual cycle and menopausal status [57]. In the simplest terms, the menstrual cycle can be divided into two phases that are separated by ovulation: follicular (begins at the onset of menses) and luteal (post ovulation). These phases can be further divided into the early, mid and late phases for each, with or without the inclusion of ovulation as a discrete phase. As such, studies involving eumenorrheic women report phases on a continuum from two to seven. Furthermore, the basis for this taxonomy is often unclear; i.e., the phases are linked to poorly defined or undefined ovarian steroid profiles. Rather than continue to dispute the name of menstrual cycle phases, a consensus is needed on the hormonal profiles of interest, such that testing timepoints and the determination of eligible data can be based on an a priori decision. Table 3 and Fig. 4 show four distinct hormonal profiles, which represent significant changes in both oestrogen and progesterone concentrations. These four profiles could be used to investigate the effects of ovarian steroids on physiology, health and performance.

### 2.3 General Guidance

Some methodological issues can affect all sport and exercise science studies with women as participants; these points are described in Table 4. One consideration is the use of “unclassified” women, viz. where the reproductive profile of the participants is not stated. In some studies, it is relevant to describe the menstrual characteristics of the participants, but not necessary to measure ovarian steroid levels. It is important to balance the internal and external validity of a study, such that the translational reach and impact of the data are not limited. The research design should be suitable to answer the research question. For example, if a study is designed to examine the effects of menstrual cycle phase on an outcome, then biochemical confirmation of the phase is warranted alongside self-reported menstrual characteristics (e.g., last menses), whereas if a study is designed to examine the physical/performance characteristics of a female sports team, then a description of the population (i.e., solely self-reported menstrual cycle phase) may be sufficient. As such, the research question should clearly indicate if the intention is to attribute an outcome to a specific hormonal profile or to observe the characteristics/responses of a clearly defined, mixed group of sportswomen or exercisers.

### 3 Discussion

#### 3.1 Definition of ‘Woman’

Herein cisgender females are described and defined based on ovarian steroid concentrations. Transgender females and women with differences in sexual development have not been characterised but require and deserve further clear research parameters to better understand their physiology. The diversity in female reproductive endocrinology makes it difficult to title and define women based on reproductive hormonal profile alone. As such, it can be challenging for researchers to decide on the inclusion/exclusion criteria for participant recruitment; determine the methods by which this criteria can be established; and use the eligibility criteria to inform the research design.

- Example 1; a researcher wishing to investigate potential effects of the menstrual cycle on exercise performance needs to decide: if they will use eumenorrheic or naturally menstruating women (see Table 1 for delineation of terminology); how they will confirm eumenorrhea; when in the cycle they will test to ensure different hormonal environments.
- Example 2; a researcher wishing to use oral contraceptive pill (OCP) users will need to decide which role they will fulfil (i.e., control or experimental sample [56]):
  - OCP users can be used as a control group, wherein cyclical fluctuations in oestrogen and progesterone experienced during the menstrual cycle can be compared to consistently downregulated sex hormone levels. The researcher then needs to decide whether to compare with the active pill phase or the non-active pill phase. For example, if the non-active pill phase is compared with the early follicular phase, then it is likely that the
| Consideration | Rationale (intended to…) | Pros (could…) | Cons (could…) |
|---------------|--------------------------|---------------|---------------|
| Define *puberty* as the onset of menarche [50] | Increase accuracy and validity of the population definition | Reduce between study variability in describing the population studied | Increase timescale of the study in order to recruit participants who fit the criteria |
| Define *peri-puberty* as the time around puberty | | Need to be aware of other physical and endocrine indicators of puberty outside of menarche (e.g., maturation of the genital organs, development of secondary sex characteristics; Tanner stages; oestrogen and progesterone concentrations) |
| Define *adrenarche* as activation of adrenal androgen production; usually occurs before gonadarche [51] | Increase homogeneity of hormonal profiles | Reduce between participant variability in hormone status | Reduce availability of eligible participants |
| Define *gonadarche* as activation of reproductive glands leading to menarche [51] | Increase consistency of terminology | Reduce between study variability in describing the population studied | Increase timescale of the study if the condition needs to be confirmed prior to the commencement of data collection |
| Define *primary amenorrhea* as failure to reach menarche by age 15 years when development of secondary sexual characteristics is evident, or by age 14 years when no secondary sexual characteristics are present [52, 53] | | | Increase number of participants who need to be excluded (during or retrospectively) from the study if the condition was not confirmed prior to commencement of the study |
| Define *eumenorrhea* as menstrual cycle lengths ≥ 21 days and ≤ 35 days resulting in 9 or more consecutive periods per year, plus evidence of LH surge, plus correct hormonal profile, plus no HC use 3 months prior to recruitment | | | |
| Define *anovulatory* as those who experience menstruation but do not ovulate (ovulation cannot be detected by urinary LH surge or confirmed by hormone concentrations via blood sample analysis) [49, 55] | | | |
| Define *luteal phase deficiency* as cycles with less than 16 nmol·L⁻¹ of progesterone, when a single luteal phase progesterone measurement is taken [48] | | | |
| Define *oligomenorrhea* as those with cycle length > 35 days [54] | | | |
| Define *secondary amenorrhea* as the absence of ≥ 3 consecutive periods in non-pregnant women with past menses [54], which can be caused by polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, or primary ovarian insufficiency [55] | | | |
### Table 1 (continued)

| Consideration                                                                 | Rationale (intended to…)                                    | Pros (could…)                                                                 | Cons (could…)                                                                 |
|------------------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Define naturally menstruating women as those who experience menstruation, with menstrual cycle lengths ≥ 21 days and ≤ 35 days, but without confirmed ovulation [ovulation was not confirmed by urinary LH surge or verified by hormone concentrations via blood sample analysis] | Increase accuracy and validity of the population definition | Reduce unfounded assumption that ovulation, and thus eumenorrhea, has been established Reduce between study variability describing the population studied | Increase timescale of the study in order to recruit participants who fit the criteria |
| A priori exclusion of participants with self-reported or diagnosed menstrual irregularities for eumenorrheic studies. | Increase homogeneity of hormonal profiles | Reduce between participant variability in hormone status Increase validity of the data | Reduce availability of eligible participants for eumenorrheic studies |
| Menstrual irregularities refer to perturbations of the eumenorrheic menstrual cycle, such as amenorrhea, anovulation, oligomenorrhea etc | | | |
| A posteriori exclusion of participants with observed or implied menstrual irregularities for eumenorrheic studies | | | Increase number of participants who need to be excluded (during or retrospectively) |
| No HC use ≥ 3 months prior to recruitment for study on eumenorrheic participants | Increase likelihood that an eumenorrheic cycle and its typical hormonal profile has been re-established | Reduce occurrence of atypical hormonal profiles not fitting the eumenorrheic definition | Reduce availability of eligible participants for eumenorrheic studies Increase timescale of the study as the condition needs to be met prior to recruitment |
| HC use ≥ 3 months prior to recruitment for HC studies | Increase likelihood that eumenorrheic cycle has been removed and replaced by a hormonal profile indicative of HC use | Reduce occurrence of atypical hormonal profiles not fitting the characterisation of HC users | |
| Define HC users as those taking any type of contraceptive capable of altering the endogenous hormonal milieu. Please note that HC also influence other aspects of metabolism, which are beyond the scope of this paper | Increase accuracy and validity of the population definition | Reduce between study variability in describing the population studied | N/A |
| Consideration                                                                 | Rationale (intended to…)                                                                                     | Pros (could…)                                                                                     | Cons (could…)                                                                                       |
|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Report the type (e.g., OCPs, implants, injections, intrauterine devices/coils that are hormone releasing and NOT copper-based, vaginal rings, contraceptive transdermal patches) and formulation (e.g., mono, bi or triphasic; combined or progesterone-only; names and concentration of exogenous hormones) of HC used | Increase reliability of studies Increase validity of findings Increase homogeneity of hormonal profiles (both endogenous and exogenous) | Reduce between participant variability in hormone status Reduce between study variability in describing the population studied Increase number of participants who need to be excluded as they do not know the exact type or formulation of HC used | Increase timescale of the study whilst trying to recruit a sufficient sample size on the same brand/type of OCP Reduce generalisability of the findings Increase timescale of the study in order to recruit participants who fit the criteria Increase timescale of the study in order to recruit participants who fit the criteria |
| One brand/type of OCP per group of participants [56]. Clearly identify exogenous hormone names and concentrations in each OCP, as well as androgenicity |                                                                                                             | Reduce between participant variability in hormone status Reduce between study variability in describing the population studied | Reduce number of participants who need to be excluded as they do not know the exact type or formulation of HC used |
| Define the first trimester as first 13 weeks of pregnancy [54]                |                                                                                                             |                                                                                                  |                                                                                                  |
| Define the second trimester as the time from week 14 to week 27 of pregnancy [54] |                                                                                                             |                                                                                                  |                                                                                                  |
| Define the third trimester as the time from 27 weeks of pregnancy onwards [54] |                                                                                                             |                                                                                                  |                                                                                                  |
| Define full term as when a pregnancy is a normal duration (i.e., 37–42 weeks gestation) [54] |                                                                                                             |                                                                                                  |                                                                                                  |
| Define postpartum as the 12 months following parturition                       |                                                                                                             |                                                                                                  |                                                                                                  |
| State gestation (i.e., the length of time, in days or weeks, that a baby is in the uterus) |                                                                                                             |                                                                                                  |                                                                                                  |
| State gravidity (i.e., number of times that a woman has been pregnant, including miscarriages and abortions) |                                                                                                             |                                                                                                  |                                                                                                  |
| State parity (i.e., number of times that a woman has given birth to a foetus with a gestational age of 24 weeks or more, regardless of whether the child was born alive or was stillborn) |                                                                                                             |                                                                                                  |                                                                                                  |
| State singleton or multiple pregnancy                                          |                                                                                                             |                                                                                                  |                                                                                                  |
| Define peri-menopause as the time around the occurrence of the menopause when the ovaries gradually produce less oestrogen [57] |                                                                                                             |                                                                                                  |                                                                                                  |
| Define menopause as the time when menstruation surceases; i.e., characterised by sporadic amenorrhea. *Please note that this is the transitional time between peri- and post-menopause |                                                                                                             |                                                                                                  |                                                                                                  |
| Consideration                                                                 | Rationale (intended to…)                                                                 | Pros (could…)                                                                 | Cons (could…)                                                                 |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Define post-menopause as the time after which a woman has experienced 12   | Increase homogeneity of hormonal profiles                                                | Reduce between participant variability in hormone status                      | Reduce availability of eligible participants if the condition needs to be      |
| consecutive months of amenorrhea and is characterised by <118 pmol·L⁻¹ of   | Increase consistency of terminology                                                      | Reduce between study variability in describing the population studied         | confirmed prior to the commencement of data collection                        |
| oestrogen, <4.4 nmol·L⁻¹ of progesterone and follicle stimulating hormone > 25 |                                                                           |                                                                                  | Increase number of participants who need to be excluded (during or retrospectively) if the condition was not confirmed prior to commencement of the study |
| IU·L⁻¹ [57]                                                                  |                                                                           |                                                                                  | Increase the time burden to identify participants with no, or a consistent set of, menopausal symptoms capable of affecting the intended outcome |
| Consider menopausal symptoms [58]                                            | To limit the effects of menopausal symptoms on outcomes                                 | Reduce the likelihood that effects are indirectly due to symptoms rather than directly due to changes in hormones |                                                                                  |
| Define HRT users as those taking any type of HRT capable of altering the     | Increase accuracy and validity of the population definition                            | Reduce between study variability in describing the population studied         | N/A                                                                            |
| endogenous hormonal milieu (e.g., tablets, skin patches, gels, implants,    |                                                                           |                                                                                  |                                                                                  |
| vaginal creams, pessaries or rings; combined or oestrogen only; cyclical or  |                                                                           |                                                                                  |                                                                                  |
| continuous)                                                                   |                                                                           |                                                                                  |                                                                                  |
| Report the type and formulation of HRT used                                   | Increase reliability of studies                                                          | Reduce between participant variability in hormone status                      | Increase number of participants who need to be excluded as they do not know the exact type or formulation of HRT used |
|                                                                              | Increase validity of findings                                                            | Reduce between study variability in describing the population studied         |                                                                                  |

Considerations without a reference have been developed by the authors for this statement

*HC hormonal contraceptives, HRT hormone replacement therapy, OCP oral contraceptive pill, LH luteinising hormone, NA not applicable*

*Please note that polycystic ovary syndrome affects between 2.2% and 26% of women worldwide, based on data from the World Health Organisation [59]*

*Please note that for women with functional hypothalamic amenorrhea (especially with the female athlete triad), this condition should be immediately corrected*
| Consideration                                                                 | Rationale (intended to…)                                                                 | Pros (could…)                                                                 | Cons (could…)                                                                 |
|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Take into account the changes in androstenedione prior to the onset of puberty | Increase breadth of data on reproductive age by considering the peri-pubertal period     | Increase understanding of the peri-pubertal changes in physiological functioning and athletic performance | Increase timescale of the study in order to identify and group participants along these spectrums |
| (e.g., the initial increase in androstenedione has been noted 18 to 12 months prior to the onset of puberty) | [60]                                                                                      |                                                                               |                                                                               |
| Take into account the changes in oestrogen prior to the onset of puberty     | Reduce assumption that once menarche has been initiated all girls have fully eumenorhеic cycles | Reduce between participant variability in hormone status                      |                                                                               |
| (e.g., the initial increase in oestrogen has been noted 12 and 6 months prior to the onset of puberty) | [60]                                                                                      |                                                                               |                                                                               |
| Take into account the time scale of establishing a eumenorrheic cycle: menarche follows an anovulatory cycle; menstrual cycles during the 1st year after menarche are typically irregular and anovulatory, ranging in duration from 21 to 45 days; by 3 years post-menarche, > 90% of girls have ≥ 10 menstrual cycles per year with an average menstrual interval of 36.5 days; cycles can remain irregular until the 5th year post-menarche | [61]                                                                                      |                                                                               |                                                                               |
| Define menstrual cycle phases based on hormonal profiles (see Table 3), verified by blood analysis with inter and intra-assay variability reported or other robust biochemical methods | Increase reliability of studies Increase validity of findings | Reduce likelihood of grouping non-homogeneous hormonal profiles Reduce inconsistency in phase definitions between studies | Increase timescale of the study in order to recruit participants who are willing to undertake blood sampling Increase cost of the study |
| Track and establish menstrual cycle characteristics for ≥ 2 months prior to testing. Tracking can be achieved by denoting the first and the last day of menstruation on a calendar for each cycle. Corroboration can be achieved by confirmation of ovulation and hormone concentrations | Reduce within participant variation in menstrual cycle characteristics Reduce likelihood of including participants with menstrual irregularities in eumenorrheic studies Increase ability to accurately predict testing timepoints (i.e., phases) Reduce variability of the data | Increase timescale of the study due to the long lead-in time Increase burden on participants to track their cycles before the experimental aspect of the study | Increase timescale of the study due to the repeated measures Increase burden on participants to repeat all of the testing sessions Increase chance of missing a positive ovulation result in participants who do not comply or adhere to conducting the test at the same time of day Increase likelihood of overlooking LPD as this method does not exclude LPD cycles |
| Outcome measures should be repeated in a second cycle                       | Reduce risk of including anovulatory women in eumenorrheic studies Reduce chance of a false positive result by the participant from an at-home interpretation | Increase likelihood of overlooking LPD as this method does not exclude LPD cycles |                                                                               |
| Use urinary ovulation kits to establish the mid-cycle surge in LH; visual confirmation should be provided to the researcher | Reduce variability of the data | Increase timescale of the study due to the long lead-in time Increase burden on participants to track their cycles before the experimental aspect of the study | Increase likelihood of overlooking LPD as this method does not exclude LPD cycles |
| [58, 63, 64] | | | |
| Consideration | Rationale (intended to...) | Pros (could...) | Cons (could...) |
|---------------|---------------------------|----------------|----------------|
| Apply a posteriori exclusion of data from testing timepoints which do not comply with the theoretical (see Fig. 2 and Fig. 3) or stipulated (see Table 3) differences in reproductive hormone concentrations in menstrual cycle studies | Ensure that the intended reproductive profiles were assessed | Reduce likelihood of grouping non-homogenous hormonal profiles | Increase number of participants who need to be excluded (retrospectively) as a result of not fitting the inclusion criteria |
| Stipulate and take into account OCP-taking (i.e., active OCP) days and OCP-free (i.e., inactive/placebo OCP) days: (i) The endogenous concentration of oestrogen and progesterone rises during the OCP free/inactive/placebo days [65, 66] (ii) The concentration of exogenous hormones increases during active OCP intake: for example, for a combined monophasic OCP ethinyl estradiol (a type of exogenous oestrogen) increases twofold from day 1 of active OCP to day 21 [66, 67] and progestin increases threefold from day 1 of active OCP to day 8–11 and then maintains that level [67, 68] | Increase homogeneity of hormonal profiles | Reduce between participant variability in hormone status | Increase timescale of the study if several conditions need to be assessed |
| Take into account the rising concentrations of oestrogen and progesterone throughout each trimester of pregnancy | | | Increase timescale of the study in order to identify and group participants along this spectrum |
| Take into account the large variation in hormonal profiles associated with the peri-menopause, menopause and post-menopause, thus treating these as separate categories of women based on the criteria outlined in Table 1 | | | |

Considerations without a reference have been developed by the authors for this paper. *OCP* oral contraceptive pill, *LPD* luteal phase deficiency, *LH* luteinising hormone
Table 3  Proposed menstrual cycle phase definitions based on hormonal profiles (see Fig. 4)

| Recommendation | Rationale (intended to…) | Pro | Con |
|----------------|--------------------------|-----|-----|
| **Phase 1**: indicated by the onset of bleeding until day 5 | Capture the lowest concentrations of oestrogen and progesterone | Easy to determine due to obvious physical cue (i.e., bloody discharge) | Can be difficult to predict in those with variable cycle length therefore requiring reactive testing sessions (i.e., participant alerting the researcher on day 1 of bleeding and then both parties having availability for testing within the next 4 days) |
| Oestrogen and progesterone levels are low | | | |
| **Phase 2**: occurs in the 14–26 h prior to ovulation and the LH surge | Capture the highest oestrogen concentration, while progesterone remains low | Enables the biggest difference between oestrogen and progesterone to be investigated | Difficult to predict without daily blood samples for the determination of oestrogen and progesterone |
| Oestrogen higher than during phase 1, 3 and 4 and progesterone higher than during phase 1, but lower than 6.36 nmol·L⁻¹ | | | |
| **Phase 3**: indicated by a positive urinary ovulation kit and lasts 24–36 h | Capture a medium oestrogen concentration, while progesterone remains low | Easy to establish due to the positive LH surge captured by the ovulation kit | Relies on having multiple ovulation kits available for each participant (cost) and requires reactive testing sessions (i.e., participant alerting the researcher to the positive result and then both parties having availability for testing within the next 24–36 h) |
| Oestrogen higher than phase 1 but lower than phase 2 and 4 and progesterone higher than phase 1 but lower than 6.4 nmol·L⁻¹ | | | |
| **Phase 4**: + 7 days after ovulation has been confirmed | Capture the highest concentration of progesterone and a high concentration of oestrogen | Easy to establish in those with eumenorrheic cycles as it typically occurs within 7 days of confirmed ovulation | Relies on the confirmation of ovulation |
| Oestrogen higher than phase 1 and 3 but lower than phase 2 and progesterone > 16 nmol·L⁻¹ | | | |

LH luteinising hormone

These recommendations have been developed using information from the following sources: McGovern et al. [69]; Tsampoukos et al. [70]; Janse de Jonge et al. [48]; Elliott-Sale et al. [71]. The phases described in Table 3 are referred to as number (i.e., 1–4), rather than names (i.e., follicular, ovulatory and luteal), to reduce the misidentification or mislabelling of phases. This should ensure that phases are described based on quantifiable metrics rather than ambiguous terms. In order to draw comparisons with previous literature the following matches can be used: phase 1 with the ‘early follicular’ phase; phase 2 with the ’late follicular’ phase; phase 3 with the ‘ovulatory’ phase; and phase 4 with the ‘mid-luteal’ phase. To date, no consensus has been reached within sport and exercise science on the nomenclature used to describe menstrual cycle phases and their corresponding hormonal profiles.
Fig. 2 Oestrogen reference ranges from three different sources\textsuperscript{1,2,3} for the follicular (F), ovulatory (O) and luteal (L) phases of the menstrual cycle. All sources are clinical reference ranges from different National Health Service Trusts in the UK and are based on the manufacturers’ laboratory reference ranges. This figure illustrates the differences in the reference ranges for each of the three prevailing oestrogen phases of the eumenorrheic menstrual cycle and suggests that additional context is required (e.g., blood sample taken on day two of bleeding, thus allowing the comparison with the follicular range; blood sample taken 12 h after ovulation was denoted by a positive urinary luteinising hormone test kit, thus allowing comparison with the ovulatory range; blood sample taken seven days after ovulation was denoted by a positive urinary luteinising hormone test kit, thus allowing comparison with the luteal range values).

Fig. 3 Progesterone reference ranges from three different sources\textsuperscript{1,2,3} for the follicular (F) and luteal (L) phases of the menstrual cycle. All sources are clinical reference ranges from different National Health Service Trusts in the UK and are based on the manufacturers’ laboratory reference ranges. This figure illustrates the differences in the reference ranges for each of the two prevailing progesterone phases of the eumenorrheic menstrual cycle and suggests that additional context is required (e.g., blood sample taken on day two of bleeding, thus allowing the comparison with the follicular range; blood sample taken seven days after ovulation was denoted by a positive urinary luteinising hormone test kit, thus allowing comparison with the luteal range values).

Fig. 4 Visual overlay of the hormonal changes across an idealised 28-day menstrual cycle indicating when each phase begins and ends as described in Table 3. The solid gold line represents oestrogen the short dash purple line represents luteinising hormone and the long dash green line represents progesterone. The black dots represent the mean concentration of oestrogen during each phase and the black diamonds represent the mean concentration of progesterone in each phase.
| Consideration | Rationale (intended to…) | Pros (could…) | Cons (could…) |
|---------------|--------------------------|---------------|---------------|
| Employ a single-blind design; although participants cannot be blinded, the researcher can be blind to the intended testing timepoint | Protect against bias | Reduce unintentional bias from the researcher to the participant | Increase staffing as an independent person is needed to undertake the blinding process |
| Do not use unclassified (i.e., not stating reproductive status) women as participants even if you are not concerned by the potential influence of reproductive hormones on your outcome measure | Increase homogeneity of hormonal profiles | Reduce between participant variability in hormone status | Reduce the availability of eligible participants |
| Standardise, by quantitative means, time of day, prior exercise, caffeine ingestion, dietary intake and nutritional supplementation, alcohol consumption and smoking as these have been shown to affect the concentration of reproductive hormones | Control extraneous variables | Allow the investigation of X on Y, without the influence of Z | Adds more requirements on the participants by asking them to standardise a large number of variables over a set period of time |
| Use the term “withdrawal bleed” rather than “period” when referring to the bleed experienced by OCP users | Stop OCP users misidentifying themselves as eumenorrheic based on bleeding patterns | Education; informing women and researchers about the differences between hormonal contraceptive users and non-users | |
| Do not use the terms “menstrual cycle” and “periods” synonymously | Dispel the myth that they are the same things and that these terms can be used interchangeably | Education; informing women and researchers about menstrual cycles and how periods are just one aspect of that cycle | |
| Do not impose any menstrual cycle language upon HC users (i.e., trying to match certain days of the OCP cycle with eumenorrheic phase descriptions, e.g., calling the first five days of OCP taking as the early follicular phase of the menstrual cycle) | Prevent confusion between hormonal contraceptive users and non-users | Allows HC users to describe their own status without adding unnecessary complexity or without misperception | |
| Report gestational age based on ultrasound dating rather than on last menstrual period | Increase the accuracy of reporting of gestational age | Reduce the ambiguity in defining participants in studies involving pregnant women | |
| Consider the timescale for resumption of eumenorrheic cycles following childbirth (i.e., in the postpartum period), given that this varies considerably between women | Reduce the assumption that all postpartum women who do not use hormonal contraceptives have eumenorrheic cycles | Reduce ambiguity in defining participants in studies involving postpartum women | |
| Do not use the term post-menopausal based on participants’ age solely | Protect against including irrelevant participants and to increase the homogeneity of hormonal profiles | Reduce between participant variability in hormone status | Increase the time and economic burden to correctly identify and confirm post-menopausal status |
| Do not report gynaecological age (i.e., number of years from menarche to recruitment in the study) as a characteristic of menstrual function (i.e., to illustrate the number of years with eumenorrheic menstrual cycles) | Reduce the assumption that the time between menarche and recruitment is filled with eumenorrheic cycles | Increase validity of the data | |
hormonal environments will be very similar between the two groups. If the mid-luteal phase is compared with the active pill phase, the hormonal environments between groups will be different. The researcher will also need to consider the type of OCP being used (i.e., oestrogen and progesterin formulations and concentrations; monophasic, biphasic, triphasic) and the duration of usage, ensuring this is similar for the whole control group of OCP users.

- OCP users can also be considered as an experimental group, wherein (i) the effects of low endogenous oestrogen and progesterone levels can be investigated and/or (ii) the effects of exogenous oestrogen and progesterin can be examined. In this case the researcher needs to decide which hormonal environments to compare, early in the non-active pill phase (with low endogenous and exogenous hormone levels), late in the non-active pill phase (with increasing endogenous oestrogen and low exogenous hormones), early in the active pill phase (with increasing exogenous hormone levels) or late in the active pill phase (with highest exogenous hormone levels). Again, the researcher will need to consider the type of OCP being used and ensure this is similar for the whole control group of OCP users and/or consider comparison between different types of OCP.

Example 3; a researcher wishing to conduct menopause-related study needs to decide which menopausal phases to include and how to define those phases; whether or not to include HRT users or those with ovarian concerns that have resulted in hormonal conditions similar to menopause; if post-menopausal women are included, how to define the time that the participants have been post-menopausal [72]. As such, we propose that:

(i) sample populations are chosen based on the research question;
(ii) participants are clearly named and described based on their reproductive characteristics;
(iii) hormonal profiles are used to inform the experimental design.

These steps should help alleviate the ambiguity surrounding the classification of women previously seen in sport and exercise studies that has led to considerable sampling heterogeneity and has hindered meaningful comparison between studies.

### 3.2 Study Validity

The validity of studies, or lack thereof, in sport and exercise science using women as participants is rarely discussed. The considerations described herein are designed to increase the internal validity through adequate quality control as a result...
of stringent recruitment strategies (e.g., using predetermined population definitions and strict inclusion/exclusion criteria) and appropriate experimental design (e.g., a priori classification of hormonal profile associated with each testing timepoint and post priori exclusion of data not meeting the stipulated terms). These measures should help to ensure that the results reflect the truth in the population studied rather than methodological errors [73]. At present, given the lack of clarity on either the direction or magnitude of potential effects of ovarian steroids on physical performance, maximising internal validity should be considered a research priority. The external validity of studies involving women as participants is often more difficult to increase due to the large inter and intra-individual variability in ovarian hormone concentrations; by reducing some of this variation through precise recruitment and testing, the external validity is lessened, and thus generalisability is reduced. These issues can be somewhat overcome through field-based testing and by testing entire teams, which could help maximise the translational potential of performance-based research in women.

3.3 Inclusion of Research with Women as Participants

Until recently, women were less represented in elite sport. Women accounted for only 2.2% of the athletes in the Paris Olympics in 1900, but they are predicted to account for an estimated high of 48.8% in the next Olympic Games [74]. Therefore, the time is right to shift more attention to women as participants in sport and exercise science research, especially given that often the research findings that are based on male participants are neither applicable nor generalizable to women. It is not appropriate to exclude women from sport and exercise science research for any reason, especially on the basis of convenience, i.e. excluding women as participants due to the potential confounding effect of female hormone fluctuations, or cost, i.e., excluding women as participants because they can be more expensive than men to study due to the extra time (e.g., repeated measures across a menstrual cycle) and resources (e.g., blood samples for the determination of ovarian steroid levels) needed to produce high-quality data. Unfortunately, it is evident that many researchers have avoided using female participants with data indicating just 4 to 13% of articles from leading journals in sports and exercise science included only women as participants [15]. So even though some research has focussed on the effects of ovarian steroids on performance, health and physiology, the small quantity of research in this area limits our understanding of the topic. Furthermore, the heterogeneity in study populations (e.g., eumenorrheic, OCP user, post-menopausal) and large variation in research designs (e.g., definition of menstrual cycle phase, oral contraceptive pill consumption or withdrawal) has resulted in many conflicting findings in sport and exercise science research with women as participants. To improve our understanding of many female specific topics, undoubtedly more high-quality research is warranted to overcome the heterogeneity and ambiguity seen in the limited number of studies in this area to date. Women account for half the world-wide population, therefore a willingness to study women as participants in sport and exercise science needs to be fostered and funding needs to be made available to achieve equivalence in knowledge about the female sex.

3.4 Limitations of the Statement

Although this paper has covered many aspects of the reproductive ageing female (i.e., from puberty to the menopause), it has not covered every perturbation of the menstrual cycle [75] or every type of hormonal contraceptive [76] or all aspects of (post) menopausal hormonal therapy. In addition, medications known to influence the hypothalamic-pituitary-ovarian axis are beyond the scope of this statement [77].

4 Conclusions

In order to improve the quality of future research in sport and exercise science with women as participants, more researchers need to accept the challenges of working in this area and embrace the means and mechanisms to produce high quality scientific studies on essentially half the world’s population. The considerations presented in this paper are not intended to be the panacea for studies on sportswomen; instead they are intended to guide readers to adopt good practice in this area and prompt further consideration of the issues involved in women-based sport and exercise science studies. As every woman’s menstrual cycle is different and can change across the lifespan, there might never be a universal blueprint that research studies and practitioners can exclusively use to direct training and performance; however, if we understand and appreciate how ovarian hormones affect different physiological systems, we can use this knowledge to tailor exercise programmes for women in response to the reproductive events throughout their lifespan.

Declarations

Funding No funding was received for this work.

Conflicts of interest Kirsty Elliott-Sale, Clare Minahan, Xanne Janse de Jonge, Kathryn Ackerman, Sarianna Sipilä, Naama Constantini, Constance Lebrun and Anthony Hackney declare that they have no conflicts of interest relevant to the content of this article.

Ethics approval Not applicable.
Consent to participate Not applicable.
Consent for publication Not applicable.
Availability of data and material Not applicable.
Code availability Not applicable.

Author contributions KES wrote the first draft of the manuscript. ACH, CLM and XAKJDJ revised the original manuscript. SS added content regarding the menstrual phase; KEA added content regarding endocrine profiles; CML added content regarding the menstrual cycle and hormonal contraceptives; NWC added content regarding the application and scope of the work. All authors read and approved the final manuscript.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Insler V, Melmed H, Mashiah S, Monselise M, Lungenfeld B, Rabau E. Functional classification of patients selected for gondodotropic therapy. Obstet Gynecol. 1968;32(5):620–6.
2. Collins BC, Arpke RW, Larson AA, Baumann CW, Xie N, Cabelka CA, et al. Estrogen regulates the satellite cell compartment in females. Cell Rep. 2019;28(2):368–381.e6.
3. Sipilä S, Finner T, Kovanen V. Estrogen influences on neuromuscular function in post-menopausal women. Calcif Tissue Int. 2015;96(3):222–33.
4. Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ. 2007;31(1):26–33.
5. Wiik A, Ekman M, Johansson O, Jansson E, Esbjornsson M. Expression of both oestrogen receptor alpha and beta in human skeletal muscle tissue. Histochem Cell Biol. 2009;131:181–9.
6. Hackney AC, McCracken-Compton MA, Ainsworth B. Substrate responses to submaximal exercise in the midfollicular and midluteal phases of the menstrual cycle. Int J Sport Nutr. 1994;4(3):299–308.
7. Birch K, Reilly T. The diurnal rhythm in isometric muscular performance differs with eumenorrheic menstrual cycle phase. Chronobiol Int. 2002;19(4):731–42.
8. Savage KJ, Clarkson PM. Oral contraceptive use and exercise-induced muscle damage and recovery. Contraception. 2002;66(1):67–71.
9. Isacco L, Duché P, Boisseau N. Influence of hormonal status on substrate utilization at rest and during exercise in the female population. Sports Med. 2012;42(4):327–42.
10. Macnutt MJ, De Souza MJ, Tomczak SE, Homer JL, Sheel AW. Resting and exercise ventilatory chemosensitivity across the menstrual cycle. J Appl Physiol. 2012;112(5):737–47.
11. Boss L, Kang DH, Marcus M, Bergstrom N. Endogenous sex hormones and cognitive function in older adults: a systematic review. West J Nurs Res. 2014;36(3):388–426.
12. Herzberg SD, Motu’apua ML, Lamberti W, Fu R, Brady J, Guise JM. The effect of menstrual cycle and contraceptives onACL injuries and laxity: a systematic review and meta-analysis. Orthop J Sports Med. 2017;5(7):2329567117718781.
13. Minahan C, Ne’ill H, Sikkema N, Joyce S, Larsen B, Sabapathy S. Oral contraceptives augment the exercise pressor reflex during isometric handgrip exercise. Physiol Rep. 2018;6(5):e13629.
14. Jacobi M. The question of rest for women during menstruation. New York: G.P. Putnam’s sons; 1877.
15. Costello JT, Bieuven F, Bleakley CM. Where are all the female participants in Sports and Exercise Medicine research? Eur J Sport Sci. 2014;14(8):847–51.
16. Lebrun CM. Effect of the different phases of the menstrual cycle and oral contraceptives on athletic performance. Sports Med. 1993;16(6):400–30.
17. Frankovich RJ, Lebrun CM. Menstrual cycle, contraception, and performance. Clin Sports Med. 2000;19(2):251–71.
18. Janse de Jonge XAK. The effect of menstrual cycle and oral contraceptives on exercise performance. Sports Med. 2003;33(11):833–851.
19. Constantini NW, Dubov N, Lebrun CM. The menstrual cycle and sport performance. Clin Sports Med. 2005;24(2):e51-x.
20. Thompson B, Almarjawi A, Scuiley D. Janse de Jonge X. The effect of the menstrual cycle and oral contraceptives on acute responses and chronic adaptations to resistance training: A systematic review of the literature. Sports Med. 2020;50(1):171–85.
21. Hackney AC, editor. Sex hormones, exercise and women; scientific and clinical aspects. Switzerland: Springer; 2017.
22. Forsyth J, Roberts CM, editors. The exercising female science and its application. London: Routledge; 2018.
23. Hackney AC, Constantini N, editors. Endocrinology of physical activity in sport. 3rd ed. Switzerland: Humana; 2020.
24. Elliott-Sale KL, McNulty KL, Andsell P, Goodall S, Hicks KM, Thomas K, et al. The effects of oral contraceptives on exercise performance in females: a systematic review and meta-analysis. Sports Med. 2020;50(10):1785–812.
25. McNulty KL, Elliott-Sale KL, Dolan E, Swinton PA, Andsell P, Goodall S, et al. The effects of menstrual cycle phase on exercise performance in eumenorrheic women: a systematic review and meta-analysis. Sports Med. 2020;50(10):1813–27.
26. Carter A, Dobridge J, Hackney A. Influence of estrogen on markers of muscle tissue damage following eccentric exercise. Hum Physiol. 2001;27:626–30.
27. Joyce S, Sabapathy S, Bulmer AC, Minahan C. The effect of prior eccentric exercise on heavy-intensity cycling: the role of gender and oral contraceptives. Eur J Appl Physiol. 2014;114:1–9.
28. Minahan C, Joyce S, Bulmer AC, Cronin N, Sabapathy S. The influence of estradiol on muscle damage and leg strength after intense eccentric exercise. Eur J Appl Physiol. 2015;115(7):1493–500.
29. Hicks KM, Onambélé-Pearson G, Winwood K, Morse CI. Oral contraceptive pill use and the susceptibility to markers of exercise-induced muscle damage. Eur J Appl Physiol. 2017;117:1393–402.
30. Mackay K, González C, Zbinden-Foncea H, Peñailillo L. Effects of oral contraceptive use on female sexual salivaary hormones and indirect markers of muscle damage following eccentric exercise in women. Eur J Appl Physiol. 2019;119:2733–44.
31. Rogers SM, Baker MA. Thermoregulation during exercise in women who are taking oral contraceptives. Eur J Appl Physiol Occup Physiol. 1997;75(1):34–8.
32. Tenaglia SA, McLellan TM, Klentrou PP. Influence of menstrual cycle and oral contraceptives on tolerance to uncompensable heat stress. Eur J Appl Physiol Occup Physiol. 1999;80:76–83.

33. Stachenfeld NS, Silva C, Keefe DL. Estrogen modifies the temperature effects of progesterone. J Appl Physiol. 2000;88:1643–9.

34. Minahan C, Melnikoff M, Quinn K, Larsen B. Response of women using oral contraception to exercise in the heat. Eur J Appl Physiol. 2017;117(7):1383–91.

35. Lebrun CM, Joyce SM, Constantini NW. Effects of Female Reproductive Hormones on Sports Performance. In: Hackney A, Constantini N, editors. Endocrinology of Physical Activity and Sport. Contemporary Endocrinology. Switzerland: Humana; 2020.

36. D’Eon TM, Sharoff C, Chipkin SR, Grow D, Ruby BC, Braun B. Regulation of exercise carbohydrate metabolism by estrogen and progesterone in women. Am J Physiol Endocrinol Metab. 2002;283:E1046–55.

37. Tarnopolsky MA. Sex differences in exercise metabolism and the role of beta-estradiol. Med Sci Sports Exerc. 2008;40:648–54.

38. Oosthuysen T, Bosch AN. The effect of the menstrual cycle on exercise metabolism: implications for exercise performance in eumenorrheic women. Sports Med. 2010;40:207–27.

39. Daily JP, Stumbo JR. Female athlete triad. Prim Care. 2018;45(4):615–24.

40. Metcalf BS, Hosking J, Jeffery AN, Henley WE, Wilkin TJ. Exploring the adolescent fall in physical activity: a 10-yr cohort study (early bird 41). Med Sci Sports Exerc. 2015;47(10):2084–92.

41. Damith SC, Gigante DP, Domingues MR, Kohl HW 3rd. Physical activity change during adolescence: a systematic review and a pooled analysis. Int J Epidemiol. 2011;40(3):685–98.

42. Active lives survey: https://www.sportengland.org/know-your-audience/data/active-lives

43. Sipilä S, Törmäkangas T, Sillanpää E, Aukeye P, Kujala U, Kovanen V, et al. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. J Cachexia Sarcopenia Muscle. 2020;11(3):698–709.

44. Bondarev D, Laakkonen EK, Finni T, Kokko K, Kujala UM, Aukeye P, et al. Physical performance in relation to menstrual status and physical activity. J Cachexia Sarcopenia Muscle. 2020;11(3):698–709.

45. Bondarev D, Laakkonen EK, Finni T, Kokko K, Kujala UM, Aukeye P, et al. Physical performance in relation to menstrual status and physical activity. J Cachexia Sarcopenia Muscle. 2020;11(3):698–709.

46. Klevan EK, et al. The role of physical activity in the link between menopausal status and mental well-being. Menopause. 2020;27(4):398–409.

47. Kavel AM. Polycystic ovarian syndrome: insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. Pharmacol Rep. 2016;1:1–5.

48. Biro FM, Pinney SM, Huang B, Baker ER, Walt Chandler D, Dorn LD. Hormone changes in peripubertal girls. J Clin Endocrinol Metab. 2014;99(10):3829–35.

49. Legro RS, Lin HM, Demers LM, Lloyd T. Rapid maturation of the reproductive axis during perimenarche independent of body composition. J Clin Endocrinol Metab. 2000;85:1021–5.

50. Hackney AC, Viru A. Research methodology: endocrinologic measurements in exercise science and sports medicine. J Athl Train. 2008;43(6):631–9.

51. Miller PB, Soules MR. The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women. Obstet Gynecol. 1996;87(1):13–7.

52. Schauberg MA, Jenkins DG, Janse de Jonge XAK, Emmerton LM, Skinner TL. Three-step method for menstrual and oral contraceptive cycle verification. J Sci Med Sport. 2017;20(11):965–69.

53. Carol W, Klinger G, Jäger R, Kasch R, Brandstädt A. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations. Exp Clin Endocrinol Diabetes. 1992;99(10):12–7.

54. Spona J, Peckham EA, James R, Nevill ME. Effect of menstrual cycle phase on sprinting performance. Eur J Appl Physiol. 2010;109(4):659–67.

55. Elliott-Sale KJ, Ross E, Burden R, Hick KM. Bases Expert Statement on Conducting and Implementing Female Based Research. The Sport and Exercise Scientist. 2020;Issue 65.
Kovanen V, Aukeye P, Kokko K, Finni T, Tarkka IM, Tammelin T, et al. Design and protocol of Estrogenic Regulation of Muscle Apoptosis (ERMA) study with 47 to 55-year-old women’s cohort: novel results show menopause-related differences in blood count. Menopause. 2018;25(9):1020–32.

Patino CM, Ferreira JC. Internal and external validity: can you apply research study results to your patients? Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tislogia. 2018;44(3):183.

International Olympic Committee. https://www.olympic.org/women-in-sport/background

Authors and Affiliations

Kirsty J. Elliott-Sale1 © · Clare L. Minahan2 © · Xanne A. K. Janse de Jonge3 © · Kathryn E. Ackerman4 © · Sarianna Sipilä5 © · Naama W. Constantini6 © · Constance M. Lebrun7 © · Anthony C. Hackney8 ©

1 Sport Health and Performance Enhancement (SHAPE) Research Centre, Department of Sport Science, Nottingham Trent University, Nottingham, UK
2 Griffith Sports Science, Griffith University, Gold Coast, QLD, Australia
3 School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, NSW, Australia
4 Division of Sports Medicine, Boston Children’s Hospital; Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA
5 Gerontology Research Centre and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland
6 Heidi Rothberg Sport Medicine Centre, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
7 Glen Sather Sports Medicine Clinic and Department of Family Medicine, Faculty of Medicine and Dentistry, University of Alberta, Alberta, Canada
8 Department of Exercise and Sport Science; Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA